Enterosgel® application in nephrology and urology
Uremic toxins as well as other toxic substances get eliminated from the organism via digestive tract. Still there is a risk of re-entering inner environment of the body by unfriendly particles released to enteral lumen organism [E.A. Friedman, C. Giordano, Sparks R.C. et al.].
Enterosgel® is capable of binding the toxic metabolites and uremic toxins (Fig. 3) [8d]*, that doesn’t allow re-absorption. Clinical researches show that absorbed toxic molecules provoke the release of albumin-binding ligands [4b, 1d, 5g ,6g].
Enterosgel® supports detox function of serum albumin at the necessary sub-compensated level. It is recommended to consider that therapeutic improvements are always individual, because the dosage of Enterosgel® , treatment routine and duration plays the critical role.
Enterosgel® porous sponge-like structure substance selectively binds only the average molecular weight toxic substances removing them from the intestinal lumen. Enterosgel® maintains ideal conditions to restore mucous membrane and damaged epithelium (Fig. 1) [1g].
Healthy and restored gastrointestinal epithelium maintains immune protection and IgA secretion [7g], decreases the toxic and antigenic pressure and maintain the immune response in kidney disease patients [5d].
Enterosgel® only collects the harmful substances while passing though colon without penetrating the internal environment of the body leaving it naturally within 7 hours. Enterosgel® is highly biocompatible comparing to other sorbents and can be used long time (up to several months) for indispensable detoxification and suitable for patients with chronic diseases.
As a part of renal insufficiency treatment, Enterosgel® is efficient in eliminating not only the intoxication symptom complex, but also the other manifestations of the illness, such as the abdominal or dysuric syndrome and temperature response (Fig. 4) [1d, 4d].
Astheno-vegetative syndrome and dysuric symptoms of patients suffering from kidney issues disappeared faster as well as the allergic activity time period appeared shorter.
The clinical tests showed that values of complete blood count normalized and bacteriuria didn’t show in the urine screens (Fig. 4) [4d].
The values of complete blood count and urine analysis in clinical screening showed positive dynamics for Enterosgel® -administered patients. After a week of the treatment 20% of patients still had leucocytosis in the analyses, but the figure droped down to 10% on the 15th day.
The group of patients, that wasn’t administered Enterosgel® along with the medication course showed 35% having leucocytosis on day 7. The complete blood count values for Enterosgel® -treated group showed the norm on the day 8 to 10, when comparing to the non-treated group – ESR remained high in 63% [4d].
Patients with mild kidney issues caused by bacterial infections require 10 days Enterosgel® course, and 15 days for the moderate disease cases. Severe kidney issue cases need individual approach of Enterosgel® treatment-planning.
Enterosgel® is suitable for children to treat chronic cystitis. The urine clinical test values shows improvements and rapid normalization. Enterosgel® can be applied along with Dioxydine – instilled into urinary bladder as intra-bladder therapy. The treatment shows leukocyturia to disappear faster comparing to patients instilled with Dioxydine without Enterosgel® (Fig. 6).
Enterosgel® instillations along with other medical drugs and antibiotics allow reduce irritation of the urinary bladder tissue.
Endoscopic types of chronic cystitis patients when treated with Enterosgel® along with the medication course show improvements and complete elimination of leukocyturia. Leukocyturia disappears twice as faster when Enterosgel® is instilled comparing to treatments with 1% Dioxydine solution [9d].
The clinical analysis showed sterile urine in 97% cases for Enterosgel® -treated patients. The non- Enterosgel® group showed 60% (Dioxydine solution only). The patients not administered Enterosgel® experienced natural microflora and cultured bacterial colonies disbalance (Fig. 7) [9d].
Enterosgel® therapy along with medications showed twice as more efficiency against bacteria comparing to follow-up courses with antibacterial treatments. The intra-bladder therapy course with Enterosgel® is 10 – 14 days of regular daily instillations with the solution of Enterosgel® (20 mL) mixed in the same proportion with 1% Dioxydine solution (20 mL).
Enterosgel® promotes maintenance of a healthy functional immune system (name not amended)
Immune system is a natural barrier of our body that helps us to resist the microbes and viruses and avoid inflammatory processes to start or evolve. Endogenous intoxications cause immune reduction may cause a lot of pressure on the organisms of children suffering from kidney inflammatory diseases (acute pyelonephritis). As result phagocytic cells lose their capacity to respond to microbial infections adequately.
Enterosgel® detoxification shows significant improvements with the immunity barrier and phagocytic cells restoration in children with acute pyelonephritis (Fig. 8) [5d].
The phagocitic innate immunity of Enterosgel® -treated children tended to normalize comparing to 20% reduction experienced earlier. Normal values of phagocytic capacity of neutrophil granulocytes (NG) support phagocytosis completeness.
Non-Enterosgel® group patients hadn’t experienced any remarkable changes of phagocytic activity. By the end of the Enterosgel® course for children the laboratory tests showed that neutrophil granulocytes reduced by 44.53 % (spontaneous nitro blue tetrazolium reduction test comparing to baseline values).
Neutrophil granulocytes (NG) activity was prevented by Enterosgel® treatment. The patients who were receiving traditional therapy haven’t shown any changes in the mentioned parameters.